Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A

Conditions

Fanconi Anemia

Brief summary

This is an open, Phase I / II clinical trial to evaluate the safety and efficacy of a hematopoietic gene therapy procedure with an orphan drug consisting of a lentiviral vector carrying the FANCA gene for patients with Fanconi Anemia of Subtype A . CD34 + cells derived from bone marrow and / or mobilized peripheral blood (fresh and / or cryopreserved) from patients with Fanconi subtype A (FA-A), will be transduced ex vivo with a lentiviral vector carrying the gene FANCA (orphan drug) . After transduction the cells will be inoculated in patients in order to restore their hematopoiesis with genetically corrected stem cells.

Detailed description

The main objective of this open-label Phase I / II clinical trial is to evaluate the safety and therapeutic efficacy of a hematopoietic gene therapy procedure with an orphan drug consisting of a lentiviral vector carrying the FANCA gene for patients with Fanconi's Anemia Subtype A. The drug to be administered to the patients consists of the cellular product resulting from the transduction of autologous CD34 + cells with the therapeutic lentiviral vector PGK-FANCA.Wpre \*. The dose of cells to infuse in the patients will be that obtained from the transduction process of between 3x10\^5 and 4x10\^6 CD34 + cells / kg of patient body weight. The cells will be infused intravenously in a single dose, after complete the transduction process. Follow-up period: 3 years after infusion of transduced cells. However, patients will be monitored outside the clinical trial over a 10-year period. Follow-up of the grafted transduced cells will be performed on peripheral blood and bone marrow samples.

Río P, Zubicaray J, Navarro S, Gálvez E, Sánchez-Domínguez R, Nicoletti E, Sebastián E, Rothe M, Pujol R, Bogliolo M, John-Neek P, Bastone AL, Schambach A, Wang W, Schmidt M, Larcher L, Segovia JC, Yáñez RM, Alberquilla O, Díez B, Fernández-García M, García-García L, Ramírez M, Galy A, Lefrere F, Cavazzana M, Leblanc T, García de Andoin N, López-Almaraz R, Catalá A, Barquinero J, Rodríguez-Perales S, Rao G, Surrallés J, Soulier J, Díaz-de-Heredia C, Schwartz JD, Sevilla J, Bueren JA, FANCOLEN-1 gene therapy investigators.

2024-12-0317 citations

10.1016/s0140-6736(24)01880-4

Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia.

Río P, Navarro S, Wang W, Sánchez-Domínguez R, Pujol RM, Segovia JC, Bogliolo M, Merino E, Wu N, Salgado R, Lamana ML, Yañez RM, Casado JA, Giménez Y, Román-Rodríguez FJ, Álvarez L, Alberquilla O, Raimbault A, Guenechea G, Lozano ML, Cerrato L, Hernando M, Gálvez E, Hladun R, Giralt I, Barquinero J, Galy A, García de Andoín N, López R, Catalá A, Schwartz JD, Surrallés J, Soulier J, Schmidt M, Díaz de Heredia C, Sevilla J, Bueren JA.

2019-09-09127 citations

10.1038/s41591-019-0550-z

Interventions

PROCEDUREIV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)

BIOLOGICALGenetically Engineered Hematopoietic Stem/Progenitor Cells

Undergo infusion of genetically modified hematopoietic progenitor cell therapy

OTHERLaboratory Biomarker Analysis

Correlative studies

BIOLOGICALFilgrastim

Given subcutaneously (SC)

DRUGPlerixafor

Given SC

PROCEDUREBone Marrow Aspiration

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 21 Years

Healthy volunteers

No

Inclusion criteria

* Patients diagnosed with Fanconi Anemia complementation group A (FA-A) * Minimum age 1 year * Maximum age 21 years * Lansky Index\> 60%. * Informed consent in accordance with current legal regulations. * Number of cells to be transduced: At least 3x10\^5 purified CD34+ / kg body weight. * Negative result in the urine pregnancy test at the baseline visit for women of childbearing age, who should be committed to using an effective contraceptive method during the period of study participation.

Exclusion criteria

* Patients with an human leukocyte antigen (HLA) identical family donor. * Evidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities predicting the same in bone marrow aspirates. In this case, the studies carried out two months in advance of the patient's entry into the clinical trial will be considered valid. * Evidence that the patient to be infused has signs of somatic mosaicism, with hematologic improvement. * Any illness or concomitant process that in the opinion of the investigator incapacitates the subject for their participation in the study. * Pre-existing sensory or motor impairment\> = grade 2 according to the National Cancer Institute (NCl) criteria. * Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame	Description
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Up to 3 years after infusion of transduced cells	All adverse events will be registered for 3 years from infusion of transduced cells
Proportion of patients with at least 0.1 copy of the therapeutic vector per nucleated bone marrow or peripheral blood cells two years after infusion.	2 years after infusion of transduced cells	Detection of at least 0.1 copy of the therapeutic vector per nucleated bone marrow cell or peripheral blood cells two years after infusion.

Secondary

Measure	Time frame	Description
Proportion of patients with clinical hematological response after the infusion of autologous CD34 + cells transduced with the therapeutic lentiviral vector	2 years after infusion of transduced cells	Proportion of patients with clinical hematological response (improvement of cell blood counts at least in one hematological lineage).

Countries

Spain

Outcome results

None listed